Multinational pharma companies have long been complaining that it takes too long to get their drugs into the Chinese market, reports The Pharma Letter’s local correspondent Wang Fangqing.
The complaints were heard. On March 17, China’s Food and Drug Administration issued a draft titled ‘amended management for imported drugs registration,’ which is for public opinion until April 20.
According to the draft, China no longer requires imported drugs to get the New Drug Application approval in their home countries before applying for the registration in China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze